Alexion Pharmaceuticals, Inc. (ALXN) Tops Q3 EPS by 8c; Boosts FY11 EPS, Revs Outlook
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q3 EPS of $0.37, $0.08 better than the analyst estimate of $0.29. Revenue for the quarter came in at $204 million versus the consensus estimate of $198.94 million.
Alexion Pharmaceuticals sees FY2011 EPS of $1.25-$1.28, versus prior guidance of $1.15-$1.20 and the consensus of $1.19. Sees FY2011 revenue of $770-$775 million, versus prior guidance of $760-$768 million and the consensus of $767.40 million.
Alexion Pharmaceuticals sees FY2011 EPS of $1.25-$1.28, versus prior guidance of $1.15-$1.20 and the consensus of $1.19. Sees FY2011 revenue of $770-$775 million, versus prior guidance of $760-$768 million and the consensus of $767.40 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Yiren Digital Ltd. (YRD) Reports Q2 Loss of RMB5.11
- Acuity Brands (AYI) Tops Q4 EPS by 11c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
